PolyPid (PYPD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on the stock and has a $11.00 price target.
Ram Selvaraju has given his Buy rating due to a combination of factors, primarily centered around the progress and potential of PolyPid’s SHIELD II Phase 3 trial. The successful completion of patient enrollment in this trial, aimed at preventing surgical site infections, is a significant milestone. The independent Data Safety Monitoring Board’s recommendation to conclude the study after enrolling 800 patients, based on unblinded efficacy data, indicates a promising outlook. If the upcoming top-line results are positive, PolyPid plans to submit a New Drug Application to the FDA, potentially leading to an approval decision by mid-2026.
Additionally, PolyPid’s financial position supports the Buy rating. The company secured $14.5 million through a private placement financing, with the possibility of raising an additional $27 million upon the exercise of warrants. This financial strategy is expected to sustain operations through the anticipated approval of their drug in 2026 and possibly extend the operational runway into 2027. The combination of clinical progress and financial stability underpins the optimistic outlook for PolyPid’s stock.